-$0.24 Earnings Per Share Expected for Ocular Therapeutix, Inc. (NASDAQ:OCUL) This Quarter

Analysts forecast that Ocular Therapeutix, Inc. (NASDAQ:OCULGet Rating) will report ($0.24) earnings per share (EPS) for the current quarter, Zacks reports. Four analysts have issued estimates for Ocular Therapeutix’s earnings, with the lowest EPS estimate coming in at ($0.26) and the highest estimate coming in at ($0.21). Ocular Therapeutix posted earnings of ($0.25) per share in the same quarter last year, which suggests a positive year-over-year growth rate of 4%. The business is scheduled to issue its next quarterly earnings report on Monday, January 1st.

On average, analysts expect that Ocular Therapeutix will report full year earnings of ($0.89) per share for the current year, with EPS estimates ranging from ($1.05) to ($0.70). For the next fiscal year, analysts forecast that the firm will post earnings of ($0.68) per share, with EPS estimates ranging from ($0.94) to ($0.46). Zacks Investment Research’s earnings per share averages are a mean average based on a survey of analysts that cover Ocular Therapeutix.

Ocular Therapeutix (NASDAQ:OCULGet Rating) last announced its quarterly earnings results on Monday, February 28th. The biopharmaceutical company reported ($0.23) earnings per share for the quarter, hitting the consensus estimate of ($0.23). Ocular Therapeutix had a negative net margin of 45.00% and a negative return on equity of 26.50%. The firm had revenue of $12.31 million during the quarter, compared to analysts’ expectations of $14.18 million. During the same quarter in the prior year, the company earned ($0.23) EPS.

A number of analysts have recently weighed in on OCUL shares. Zacks Investment Research lowered shares of Ocular Therapeutix from a “hold” rating to a “sell” rating in a research note on Saturday. Piper Sandler cut their price objective on shares of Ocular Therapeutix from $16.00 to $10.00 in a research note on Friday. HC Wainwright cut their price objective on shares of Ocular Therapeutix from $14.00 to $10.00 in a research note on Tuesday, May 10th. StockNews.com started coverage on shares of Ocular Therapeutix in a research note on Thursday, March 31st. They issued a “hold” rating on the stock. Finally, JMP Securities cut their price objective on shares of Ocular Therapeutix from $30.00 to $22.00 and set a “market outperform” rating on the stock in a research note on Tuesday, March 1st. One equities research analyst has rated the stock with a sell rating, one has given a hold rating, three have given a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Buy” and a consensus price target of $16.60.

Shares of Ocular Therapeutix stock opened at $3.19 on Friday. The company has a current ratio of 7.29, a quick ratio of 7.23 and a debt-to-equity ratio of 0.65. Ocular Therapeutix has a 12-month low of $2.91 and a 12-month high of $15.32. The firm has a market capitalization of $244.86 million, a price-to-earnings ratio of -3.43 and a beta of 1.79. The firm’s 50 day simple moving average is $4.08 and its two-hundred day simple moving average is $5.37.

A number of hedge funds have recently added to or reduced their stakes in OCUL. OLD Mission Capital LLC acquired a new stake in Ocular Therapeutix during the third quarter valued at $184,000. Morgan Stanley lifted its holdings in Ocular Therapeutix by 47.1% during the second quarter. Morgan Stanley now owns 491,867 shares of the biopharmaceutical company’s stock valued at $6,974,000 after purchasing an additional 157,541 shares in the last quarter. Barclays PLC lifted its holdings in Ocular Therapeutix by 362.7% during the third quarter. Barclays PLC now owns 75,737 shares of the biopharmaceutical company’s stock valued at $757,000 after purchasing an additional 59,369 shares in the last quarter. Teacher Retirement System of Texas purchased a new position in Ocular Therapeutix during the third quarter valued at $103,000. Finally, Citigroup Inc. lifted its holdings in Ocular Therapeutix by 117.0% during the third quarter. Citigroup Inc. now owns 45,657 shares of the biopharmaceutical company’s stock valued at $457,000 after purchasing an additional 24,613 shares in the last quarter. Institutional investors own 53.94% of the company’s stock.

About Ocular Therapeutix (Get Rating)

Ocular Therapeutix, Inc, a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology. The company markets ReSure Sealant, an ophthalmic device to prevent wound leaks in corneal incisions following cataract surgery; and DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis.

Recommended Stories

Get a free copy of the Zacks research report on Ocular Therapeutix (OCUL)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Ocular Therapeutix (NASDAQ:OCUL)

Receive News & Ratings for Ocular Therapeutix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ocular Therapeutix and related companies with MarketBeat.com's FREE daily email newsletter.